Apr 17, 2024 / 02:00AM GMT
Matthew Wright - NWR Communications - Moderator
Hello, and welcome to this Neurotech investor webinar discussing three key announcements for the company that were lodged with the ASX this morning regarding its Phase 2/3 autism trial results, Phase 1/2 Rett syndrome top-line results, and a $10 million capital raising. (Event Instructions) And please note this session is being recorded.
On behalf of Neurotech today, we have the Executive Director, Dr. Thomas Duthy. I'll now hand it over to Tom. Please go ahead.
Thomas Duthy - Neurotech International Ltd - Executive Director
Thank you, Matt, and thanks, everyone, for joining today's informative webinar. We are absolutely delighted to be presenting to you very strong clinical data across two very difficult-to-treat pediatric neurological disorders in autism spectrum disorder, ASD, and Rett syndrome. So it's a great day for the company faithfully. So it's a fantastic day for these young children and their caregivers. And we sincerely thank our clinical investigators, Professor Fahey and Associate Professor
Neurotech International Ltd Investor Webinar Transcript
Apr 17, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers